Corbus Pharmaceuticals Holdings, Inc. announced the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Phase 1 trial initiates with dose escalation followed by dose optimization and concludes with dose expansion to determine the recommended Phase 2 dose.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.84 USD | -1.16% |
|
+3.09% | +628.31% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+628.31% | 474M | |
+16.23% | 122B | |
+21.43% | 116B | |
+22.15% | 27.03B | |
-21.19% | 20.36B | |
-17.05% | 16.43B | |
-17.85% | 15.91B | |
-44.35% | 15.6B | |
+57.62% | 14.94B | |
+1.70% | 13.59B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC